115 results about "Mitomycin D" patented technology

The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising a sulfonamide compound, a sulfonate compound or a salt of them, which is represented by the following formula: (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group; W represents a single bond or -CH=CH-; X represents -NH- etc.; and Y represents a carbon atom or a nitrogen atom; and Z represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil; (4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin; (7) taxol; (8) carboplatin; (9) oxaliplatin; (10) capecitabine; and (11) a salt of the above-mentioned (1) to (10).

A method of preparing and using a sterile non-toxic pyrogen-free cold extract from the leaves of Nerium oleander as a supplementary medication to cancer chemo-, hormon and / or radiotherapy to restore and / or ameliorate the immune system of the patient and / or to decrease side effects and increase the antitumor effects of radiotherapy and chemotherapeutics, particularly when used in combination with taxol, adriamycin, cisplatin, 5-fluoro-uracil, alimta, cyclophosphamide, mitomycin-C, navelbine, taxotere and topotecan, respectively, and its use in the manufacture of a medicament for the treatment of one or more cancers of bladder, kidney, liver, ovary, pancreas, testicle, uterus, and vagina as well as pleuramesotheliomas and Hodgkin's lymphomas.

The invention discloses an inducing method for directionally differentiating human embryonic stem cells to corneal endothelial cells. The method comprises the steps of: cultivating the human embryonic stem cells on a mouse embryonic fibroblast feed layer; sorting human embryonic stem cell clone groups in good state; grafting the groups on a human corneal stromal fibroblast layer processed by mitomycin C and cultivating for 7 days, wherein the human embryonic stem cells are differentiated to rosettes; separating and transferring the rosettes from the human corneal stromal fibroblast layer to a culture bottle; cultivating continuously for 7 days by using a neural crest stem cell culture medium; sorting the neural crest stem cells by a flow cytometry; adding the neural crest stem cells into the culture bottle; placing in a 5% CO2 incubator for incubating and cultivating at 37 DEG C by using a human corneal endothelial cell culture medium; changing the liquid every other day; and cultivating for about 10 days to obtain the corneal endothelial cells. The multiplication capacity of the corneal endothelial cells are similar to that of human corneal endothelial cells and the corneal endothelial cells can be transferred to 1-2 generations in vitro maximally. The corneal endothelial cells can be used as seed cells for cornea construction and transplant in tissue engineering.

The present invention provides a medicinal composition having an excellent antitumor activity. That is, it provides a medicinal composition comprising a sulfonamide compound, a sulfonate compound or a salt of them, which is represented by the following formula: (wherein ring A represents an aromatic ring which may have a substituent group; ring B represents a 6-membered unsaturated hydrocarbon ring which may have a substituent group etc.; ring C represents a 5-membered hetero-ring containing one or two nitrogen atoms, and the ring C may have a substituent group; W represents a single bond or -CH=CH-; X represents -NH- etc.; and Y represents a carbon atom or a nitrogen atom; and Z represents -NH- etc.), particularly N-(3-chloro-1H-indol-7-yl)-4-sulfamoylbenzenesulfonamide or a salt thereof, combined with at least one substance selected from (1) irinotecan hydrochloride trihydrate; (2) mitomycin C; (3) 5-fluorouracil; (4) cisplatin; (5) gemcitabine hydrochloride; (6) doxorubicin; (7) taxol; (8) carboplatin; (9) oxaliplatin; (10) capecitabine; and (11) a salt of the above-mentioned (1) to (10).

The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.

Provided herein are human embryonic stem cells and their method of culturing. In one embodiment, the human embryonic stem cells are maintained in an environment containing an extracellular matrix isolated from feeder cells and a conditioned medium pre-conditioned by the feeder cells; the feeder cells are pre-inactivated by either gamma ray radiation or by mitomycin C treatment. The cultured human embryonic stem cells remain substantially undifferentiated and maintain their pluripotency to differentiate into three germ layer cells.

The invention discloses a human umbilical cord blood hematopoietic stem cell (HSC) high-efficiency in vitro amplification technology. According to the invention, umbilical cord mesenchymal stem cells (MSCs) and umbilical cord blood plasma are used in combination for carrying out HSC in vitro amplification. A process comprises steps that: umbilical cord MSCs are cultured as a trophoblast; a special culture solution containing umbilical cord blood plasma is adopted as an amplification medium of the HSCs; and umbilical cord blood karyotes are adopted as amplification initiator cells. According to the invention, exogenous cell factors are not required to be added, treatments such as mitomycin C or gamma-ray 21Gy irradiation are not required by the trophoblast, no 3-dimensional technology is required, and the HSC high-efficiency amplification can be carried out. The technology is advantaged in low cost, convenient amplification, and low product immunogenicity. The technology is suitable for large-scaled productions. The practical application of the technology plays an important role in clinical treatments and researches.

An apparatus for preparing a pharmaceutical for transient application includes a tray having a sealed compartment, a vial of an ophthalmic formulation of mitomycin-C, a diluent carrier containing sterilized water, and a syringe that are all contained together in a single package. The component parts of the apparatus are used together to reconstitute the contents of the vial with the water in the diluent carrier, and then draw the reconstituted drug into the sealed compartment of the tray by a suction force produced by the syringe. In the tray compartment, the reconstituted drug is absorbed in an absorbent pad. The tray is opened to remove the pad and the absorbed drug from the tray compartment for use of the pad in transient application of the drug.

Methods for administering mitomycin C to a multi-drug resistant cell and for reducing the toxicity of the compound are described. In the methods, mitoymic C is provided in the form of a prodrug conjugate, where the drug is linked to a hydrophobic moiety, such as a lipid, through a cleavable dithiobenzyl linkage. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of mitomycin C in its original form. The linkage is stable under nonreducing conditions. The prodrug conjugate can be incorporated into liposomes for administration in vivo and release of mitomycin C in response to endogenous in vivo reducing conditions or in response to administration of an exogenous reducing agent.

Methods and devices for the application of beta radiation treatment following trabeculectomy for helping to prevent post-trabeculectomy wound reversion. The devices may feature a handle and a beta radiation source. The beta radiation source may include strontium-90, yttrium-90, potassium-32, or any other appropriate radiation source or combination thereof. The device may be used to expose a trabeculectomy wound to the radiation source following the surgical procedure. In some embodiments, a drug such as 5-fluorouracil or mitomycin c is used in combination.

The present invention relates to the treatment of cancer with compounds that inhibit the activity of endo-exonuclease. Endo-exonuclease has been shown to be necessary for the repair of damaged DNA. Compounds that inhibit the activity of endo-exonuclease have been shown to be particularly effective for treating cancer when used in combination with drugs that induce DNA breaks such as cisplatin and mitomycin C. These compounds have a synergistic effect when used in combination for inhibiting tumour growth. The invention includes pharmaceutical compositions for inhibiting tumour growth comprising a compound that inhibits endo-exonuclease activity. These pharmaceutical compositions preferably include compounds that induce DNA breaks. The invention includes methods of treating cancer with these pharmaceutical compositions and uses of these compositions to treat cancer. The preferred compounds that inhibit the activity of endo-exonuclease have low toxicity. One such compound is pentamidine. The invention also includes a method for diagnosing cancer and monitoring its progression. This aspect of the invention involves isolating serum from a patient; measuring the concentration of endo-exonuclease in said serum and determining whether said concentration is above a predetermined mean.

The invention discloses a mouse fibroblast and an application thereof, and belongs to the field of cell biology. The cell is named mouse fibroblast MFC / HL-041 with the preservation number of CCTCC NO:C201714. The mouse fibroblast treated by mitomycin C or irradiated by radioactive rays is used for separation and subculture of normal primary epithelial cells and primary tumor cells. Obtained humanpulmonary normal primary epithelial cells and lung cancer primary epithelial cells are fresh and live in state, tight in arrangement, clear in cell boundary, high in stereoscopic impression and polygonal when examined under a microscope. The mouse fibroblast can be used for physiological study of human or animal normal cells, a virus infection model of in-vitro normal cells, drug sensitivity tests of the in-vitro normal cells for different drugs, drug screening for individualized treatment of cancer patients as well as research and development of new anti-cancer drugs.

Anthracyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. The anthracyclines-induced CRT translocation was mimicked by inhibition of the protein phosphatase1 / GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase1 / GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anti-cancer immune responses and delineate a possible strategy for immunogenic chemotherapy.

The invention relates to a low-molecular-weight L-polyglutamine-mitomycin C with the structural formula shown in the specification and the molecular weight of 1882Da-5892Da, wherein n is equal to 1500-6000. A synthesis method comprises the following steps: dissolving polyglutamic acid into water, stirring and then separating with sephadex chromatography to take polyglutamic acid with molecular weight of 1500-6000, performing freeze-drying and then adding dioxane, N-hydroxysuccinimide, a condensing agent and an acid-binding agent, evaporating out solvents and dissolving chloroform, washing with diluted hydrochloric acid and then evaporating the chloroform layer to dryness, adding a product to HBS buffer, adding mitomycin C under stirring, and then stirring reaction liquid and concentrating to dryness, and separating by using silicon gel column chromatography to obtain the low-molecular-weight L-polyglutamine-mitomycin C. The mitomycin C is modified by utilizing low-molecular-weight L-polyglutamine, and cannot penetrate cornea due to large molecular weight; the low-molecular-weight L-polyglutamine-mitomycin C can be accumulated in pterygium tissues through EPR effect; and the release of mitomycin C can be mediated by cathepsin B enzyme in the pterygium tissues so as to achieve the treatment effect.

The invention discloses a method of utilizing human umbilical cord mesenchymal stem cells as a feed layer to culture human induced pluripotent stem cells. The method comprises the following steps: (1) preparation of the feed layer: taking the human umbilical cord mesenchymal stem cells, inoculating the cells to a culture dish until the cell confluence degree is 40-60%, adding 5-15 ug / ml of mitomycin C, processing the culture for 2-4 h, removing mitomycin C, and obtaining the feed layer; (2) culture: inoculating the human induced pluripotent stem cells to the feed layer which is prepared in the step (1), culturing, and finishing. The method can be used for effectively culturing the human induced pluripotent stem cells for a long time, is free from pollution of heterogonous cells and heterogonous proteins, and has good application prospect.

Anthracyclin-treated turn or cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclins induce the rapid, pre-apoptotic translocation of calreticulin (CRT) to the cell surface. Blockade or knock down of CRT suppressed the phagocytosis of anthracyclin-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. The anthracyclin-induced CRT translocation was mimicked by inhibition of the protein phosphatase1 / GADD34 complex. Administration of recombinant CRT or inhibitors of protein phosphatase1 / GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify CRT as a key feature determining anti-cancer immune responses and delineate a possible strategy for immunogenic chemotherapy.

The invention relates to anticancer sustained release injection which comprises sustained release microspheres and menstruum, wherein, the sustained release microspheres comprise anticancer active components and sustained release auxiliary material; the menstruum is special menstruum that contains suspending agent. The anticancer active components are fotemustine, nimustine, carmustine or combination of bendamustine and mitozolomide, docetaxel, etoposide, teniposide, vinblastine, anastrozole, tamoxifen, fluorouracil or mitomycin C; the sustained release auxiliary material is polylactic acid and polylactic acid copolymer, polyethylene glycol and polylactic acid copolymer of polyethylene glycol, terminal carboxyl group polylactic acid copolymer, EVAc, fatty acid and decanedioic acid copolymer, etc.; viscosity of the suspending agent is 100cp-3,000cp (at 25 DEG C-30 DEG C), and the suspending agent is selected from sodium carboxymethylcellulose, etc. The sustained release microspheres can also be made into sustained release implant; the injection or implant is injected or placed in or around tumor so as to reduce general reaction of the drug and selectively improve and keep local concentration for about 30-50 days. The anticancer sustained release injection can be used solely and can also promote anti-tumor effects of non-operative treatments, such as chemotherapy and / or radiotherapy, etc.

The invention discloses a method for developing and cultivating human induced pluripotent stem cells. The method is characterized by comprising the steps of a, preparing a human fibroblast-like cell feeding layer, seeding human fibroblast-like cells onto a petri dish, and processing 10mg / ml mitomycin C for three hours in advance to remove mitomycin C; b, reprogramming somatic cells, generating the human induced pluripotent stem cells, and transplanting the human induced pluripotent stem cells into the feeding layer prepared in the step a to be cultivated. By the adoption of the technical scheme, the influence of heterologous cells and heterologous protein on the induced pluripotent stem cells is avoided, transcription efficiency is high, the differentiation capacity of the induced pluripotent stem cells is not affected, the number of cultivation generations is large, life is long, and the method has huge potential clinically.

The invention belongs to the field of stem cell culture, and particularly relates to a cell culture medium and a stem cell culture method. The invention provides a stem cell culture medium. The stem cell culture medium comprises a basic culture medium, a platelet lysate, an L-Glutamine and a mitomycin c. The invention also provides a stem cell separating method. The stem cell separating method comprises the following steps that the in-vitro tissue and the stem cell culture medium are mixed to be placed in a culture flask for culturing until cells creep out from the in-vitro tissue, the in-vitro tissue is scraped; the culture of the cells is continued, when the fusion degree of stem cells in the culture flask reaches 80% to 90%, the cells are passage-cultured after digestion. The stem cell culture medium can avoid the risk that the existing stem cell culture medium contains mostly animal serum so as to introduce exogenous virus; the stem cell separating method is simple to operate.

The invention relates to an application of salvianolic acid L in preparation of medicines used for treating tumor, salvianolic acid L belongs to a phenolic acid compound which is a novel water-soluble compound with a confirmed structure extracted from a traditional Chinese medicine red sage root, a pharmacological research shows that the phenolic acid possesses anti-oxidation effect and anti-myocardial ischemia effect. According to the invention, the salvianolic acid L induces the apoptosis of tumor cells and also can kill the tumor cells. Animal experiments show that salvianolic acid L possesses certain antineoplastic activity and does not appear toxicity, and is capable of substantially enhancing antineoplastic activity of various tumor medicines 5-fluorouracil, mitomycin C and the like, the compound is expected to be used for clinical tumor treatment.

A multilocular liposome of mitomycin for preventing and treating tumor is prepared through dissolving the lipoid component (neutral phosphatide, cholesterol and neutral lipid) in organic solvent, dissolving mitomycin in buffering salt solution, mixing, emulsifying to obtain water-in-oil primary emulsion, adding external water phase containing isotonic regulator, stirring to become water-in-oil-in-water emulsion, and removing organic solvent.

The invention relates to a temperature-controlled sustained-release injection containing an anti-cancer drug, which consists of the anti-cancer drug and an amphiphilic block copolymer hydrogel and has the temperature-sensitive gelatinization feature, the temperature-controlled sustained-release injection is flowable liquid in the environment that is lower than the body temperature and can be automatically converted to the water-insoluble gel that can not flow and be biodegradable for absorption in an endotherm, thus allowing the drug to have the local sustained release in a tumor and maintain the effective drug concentration for a plurality of weeks to a plurality of months; the temperature-controlled sustained-release injection can be injected in the tumor or the tumor periphery or be arranged in the postoperative tumor cavity, thus significantly reducing the systemic reaction of the drug, strengthening the treatment effects of chemotherapy, radiotherapy and other non-surgical therapies, and being used for the treatment of the tumors in different stages. The anti-cancer drug can be vincristine, vinorelbine, navelbine, vindesine, vinleurosine, vinrosidine, cephalotaxine, bleomycin, daunomycin, aclarubicin, epirubicin, idarubicin, pirarubicin, valrubicin, mitomycin C, actinomycin D, losoxantrone, mitoxantrone, mitozolomide, temozolomide and so on.

The invention relates to a method for improving the sperm motility with Sertoli cells as the trophoblast. The method mainly includes the steps of: (1) conducting isolation culture on Sertoli cells; (2) preparing a Sertoli cell trophoblast: conducting isolation culture on Sertoli cells for 2 days to form a cell monolayer, adding mitomycin C to perform treatment for 2h so as to prepare a Sertoli cell trophoblast; and (3) acquiring sperm from an epididymis of a mature male animal, adding the sperm into a culture system adopting Sertoli cells as the trophoblast, and performing co-culture on the sperm and Sertoli cells. The method provided by the invention adopts Sertoli cells as the trophoblast for in-vitro culture of sperms in testicle and epididymis, solves the problem of low in-vitro sperm motility, enhances the motility and survival rate of in-vitro sperms, and increases the fertilization capability of sperms.

A packaged kit for performing a photodynamic laser myringotomy includes a plurality of ear needles having different shaped absorbent applicators on distal ends of the needles, a vial of a single dose of an otologic formulation of mitomycin-C, a diluent carrier containing sterilized water, and a syringe. The component parts of the kit are used together to reconstitute the contents of the vial with the water in the diluent carrier, and then draw the reconstituted drug into the syringe. A selected one of the plurality of ear needles is then communicated with the syringe. The syringe and needle are then used to inject the reconstituted drug into the absorbent pad at the end of the needle, and the absorbent pad containing the drug is used to apply the drug to the tympanic membrane. The application of the drug to the tympanic membrane prepares the membrane for a myringotomy procedure, and in particular, a photodynamic laser myringotomy.

The invention provides a preparation method for improving productivity of mitomycin C. The preparation method comprises the following steps: adding a composite precursor containing citrulline and arginine and HP-21 resin into a fermentation medium of the mitomycin C to prepare a dedicated fermentation medium; and culturing the head-shaped streptomyces generating mitomycin C respectively through a slant medium and a seed medium, then transferring to the prepared dedicated fermentation medium for culturing. Due to the action of the composite precursor containing citrulline and arginine, the content of mitomycin C in the effective compound generated by fermentation is greatly improved to 30-45 percent, so that the production cost of mitomycin C can be greatly reduced, as a result, the method for preparing mitomycin C has favorable industrial prospect.

The present invention features monoclonal antibodies LA1 or LA22 conjugated with mitomycin C, pingyangmycin or other anti-cellular agents. The present invention also features other anti-EGFR antibodies conjugated with mitomycin C or pingyangmycin. The antibodies of the present invention can be used to treat cancers, including but not limited to, those of epithelial origin, such as glioblastoma or cancer of the lung, breast, head and neck, and bladder.